Deuterated N,N-dimethyltryptamine compounds
US11471417B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2021 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | Aug 26, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, α-protio, α-deutero-N,N-dimethyltryptamine compounds, α,α-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I):
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.